[1] Muthukrishnan G, Masters EA, Daiss JL, Schwarz EM. Mechanisms of Immune Evasion and Bone Tissue Colonization That Make S. aureus the Primary Pathogen in Osteomyelitis. Curr Osteoporos Rep. 2019. 17(6): 395-404.
[2] Alvares PA, Mimica MJ. Osteoarticular infections in pediatrics. J Pediatr (Rio J). 2020. 96 Suppl 1: 58-64.[PubMed链接]
[3] Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am. 2005. 19(4): 765-86.
[4] Geurts J, Hohnen A, Vranken T, Moh P. Treatment strategies for chronic osteomyelitis in low- and middle-income countries: systematic review. Trop Med Int Health. 2017. 22(9): 1054-1062.
[5] Geraghty T, LaPorta G. Current health and economic burden of chronic diabetic osteomyelitis. Expert Rev Pharmacoecon Outcomes Res. 2019. 19(3): 279-286.
[6] Hogan A, Heppert VG, Suda AJ. Osteomyelitis. Arch Orthop Trauma Surg. 2013. 133(9): 1183-96.
[7] Pincher B, Fenton C, Jeyapalan R, Barlow G, Sharma HK. A systematic review of the single-stage treatment of chronic osteomyelitis. J Orthop Surg Res. 2019. 14(1): 393.
[8] Panemangalore M, Cherian MG. Metabolism of parenterally administered zinc and cadmium in livers of newborn rats. Chem Biol Interact. 1983. 45(3): 327-39.
[9] Reizner W, Hunter JG, O'Malley NT, Southgate RD, Schwarz EM, Kates SL. A systematic review of animal models for S. aureus osteomyelitis. Eur Cell Mater. 2014. 27: 196-212.
[10] Howell WR, Goulston C. Osteomyelitis: an update for hospitalists. Hosp Pract (1995). 2011. 39(1): 153-60.
[11] Inzana JA, Schwarz EM, Kates SL, Awad HA. Biomaterials approaches to treating implant-associated osteomyelitis. Biomaterials. 2016. 81: 58-71.
[12] Rissing JP, Buxton TB, Fisher J, Harris R, Shockley RK. Arachidonic acid facilitates experimental chronic osteomyelitis in rats. Infect Immun. 1985. 49(1): 141-4.
[13] Shao L, Zhen P, Ma Y, Gong D, Wang Y. [Comparative study of different concentrations of methicillin-resistant S. aureus in the preparation of chronic femoral osteomyelitis models]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2018. 32(4): 412-419.
[14] Jacobs G, Sandmann W. [Surgical aspects in arterial occlusion (author's transl)]. Zentralbl Chir. 1977. 102(18): 1097-01.
[15] Fukushima N, Yokoyama K, Sasahara T, Dobashi Y, Itoman M. Establishment of rat model of acute staphylococcal osteomyelitis: relationship between inoculation dose and development of osteomyelitis. Arch Orthop Trauma Surg. 2005. 125(3): 169-76.
[16] Rivas Felice J, González Herranz P, Mejía Casado A, Pérez Navarro R, Hernández Díaz R. Chronic recurrent osteomyelitis: A diagnostic and therapeutic challenge. Rev Esp Cir Ortop Traumatol. 2017. 61(1): 35-42.
[17] Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am. 2015. 97(10): 837-45.
[18] Maffulli N, Papalia R, Zampogna B, Torre G, Albo E, Denaro V. The management of osteomyelitis in the adult. Surgeon. 2016. 14(6): 345-360.
[19] Calvo C, Núñez E, Camacho M, et al. Epidemiology and Management of Acute, Uncomplicated Septic Arthritis and Osteomyelitis: Spanish Multicenter Study. Pediatr Infect Dis J. 2016. 35(12): 1288-1293.
[20] Sweeney E, Lovering AM, Bowker KE, MacGowan AP, Nelson SM. An in vitro biofilm model of S. aureus infection of bone. Lett Appl Microbiol. 2019. 68(4): 294-302.
[21] Zimmerli W, Sendi P. Orthopaedic biofilm infections. APMIS. 2017. 125(4): 353-364.
[22] Zaborowska M, Tillander J, Brånemark R, Hagberg L, Thomsen P, Trobos M. Biofilm formation and antimicrobial susceptibility of staphylococci and enterococci from osteomyelitis associated with percutaneous orthopaedic implants. J Biomed Mater Res B Appl Biomater. 2017. 105(8): 2630-2640.
[23] Demirdal T, Sen P. The significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and lymphocyte-monocyte ratio in predicting peripheral arterial disease, peripheral neuropathy, osteomyelitis and amputation in diabetic foot infection. Diabetes Res Clin Pract. 2018. 144: 118-125.
[24] Allen LL, Kalmar G, Driver VR. Treatment of a High-Risk Diabetic Patient with Peripheral Vascular Disease and Osteomyelitis. Tech Vasc Interv Radiol. 2016. 19(2): 96-100.
[25] Franchi A, Häfeli M, Scaglioni MF, Elliot D, Giesen T. The use of chimeric musculocutaneous posterior interosseous artery flaps for treatment of osteomyelitis and soft tissue defect in hand. Microsurgery. 2019. 39(5): 416-422.
[26] Meng H, Liu Y, Lai L. Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation. Acc Chem Res. 2015. 48(8): 2242-50.
[27] Arens D, Wilke M, Calabro L, et al. A rabbit humerus model of plating and nailing osteosynthesis with and without S. aureus osteomyelitis. Eur Cell Mater. 2015. 30: 148-61; discussion 161-2.
[28] Gaudin A, Amador Del Valle G, Hamel A, et al. A new experimental model of acute osteomyelitis due to methicillin-resistant S. aureus in rabbit. Lett Appl Microbiol. 2011. 52(3): 253-7.
[29] Wang Y, Cheng LI, Helfer DR, et al. Mouse model of hematogenous implant-related S. aureus biofilm infection reveals therapeutic targets. Proc Natl Acad Sci U S A. 2017. 114(26): E5094-E5102.
[30] Shirai T, Hanaoka R, Goto Y, et al. Takayasu Arteritis Coexisting with Sclerosing Osteomyelitis. Intern Med. 2018. 57(13): 1929-1934.
[31] Birt MC, Anderson DW, Bruce Toby E, Wang J. Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies. J Orthop. 2017. 14(1): 45-52.
[32] Lazzarini L, Overgaard KA, Conti E, Shirtliff ME. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis. J Chemother. 2006. 18(5): 451-60.